Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Journal of Biopharmaceutical Statistics|February 13, 2009
Evaluation of biomarkers for pharmacological activityAriel Alonso, Geert Molenberghs, Didier Renard, et al.Diabetes Research and Clinical Practice|January 28, 2014
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer studyAstrid Breitschaft, Ke Hu, Karina Hermosillo Reséndiz, et al.Journal of Clinical Pharmacology|October 2, 2007
Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjectsMichel Guillaume, Finnuala Lonsdale, Christelle Darstein, et al.Journal of Clinical Pharmacology|February 29, 2008
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjectsRebecca E Wrishko, Jasper Dingemanse, Albert Yu, et al.Endocrine|April 25, 2012
Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I studyChristoph Beglinger, Ke Hu, Ying Wang, et al.Journal of Clinical Pharmacology|September 4, 2007
Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjectsPamela A Welch, Vikram P Sinha, Ann L Cleverly, et al.Clinical Therapeutics|July 12, 2014
Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized studyXia Chen, Guoxiang Shen, Ji Jiang, et al.Clinical Pharmacokinetics|January 20, 2024
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast CancerYan Ji, Hilmar Schiller, Shu Yang, et al.Journal of Clinical Pharmacology|November 19, 2013
Effects of Subcutaneous Pasireotide on Cardiac Repolarization in Healthy Volunteers: a Single‐Center, Phase I, Randomized, Four‐Way Crossover StudyAstrid Breitschaft, Ke Hu, Christelle Darstein, et al.Journal of Clinical Pharmacology|July 19, 2023
Quantitative Assessment of Ribociclib Exposure-Response Relationship to Justify Dose Regimen in Patients with Advanced Breast CancerYan Ji, Christelle Darstein, Shu Yang, et al.Pageof 3